118 related articles for article (PubMed ID: 38527651)
21. Characteristics and prognostic analysis of patients with detected
Hashimoto T; Owada Y; Katagiri H; Yakuwa K; Tyo K; Sugai M; Fuzimura I; Utsumi Y; Akiyama M; Nagashima H; Terasaki H; Yanagawa N; Saito H; Sugai T; Maemondo M
Transl Lung Cancer Res; 2023 Sep; 12(9):1862-1875. PubMed ID: 37854155
[TBL] [Abstract][Full Text] [Related]
22. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
Zhou SL; Xin HY; Sun RQ; Zhou ZJ; Hu ZQ; Luo CB; Wang PC; Li J; Fan J; Zhou J
JAMA Surg; 2022 Jan; 157(1):59-65. PubMed ID: 34730772
[TBL] [Abstract][Full Text] [Related]
23. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B; Son J; Okoro JJ; Mira A; Patrucco E; Eum Y; Wang X; Paranal R; Wang H; Lin M; Haikala HM; Li J; Xu Y; Alessi JV; Chhoeu C; Redig AJ; Köhler J; Dholakia KH; Chen Y; Richard E; Nokin MJ; Santamaria D; Gokhale PC; Awad MM; Jänne PA; Ambrogio C
Clin Cancer Res; 2022 Apr; 28(8):1640-1650. PubMed ID: 35091439
[TBL] [Abstract][Full Text] [Related]
24. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
25. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
26. Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.
Ottaiano A; Normanno N; Facchini S; Cassata A; Nappi A; Romano C; Silvestro L; De Stefano A; Rachiglio AM; Roma C; Maiello MR; Scala S; Delrio P; Tatangelo F; Di Mauro A; Botti G; Avallone A; Nasti G
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708575
[TBL] [Abstract][Full Text] [Related]
27. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
28. Characterization of distinct types of
Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
[TBL] [Abstract][Full Text] [Related]
29. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
Hayama T; Hashiguchi Y; Okamoto K; Okada Y; Ono K; Shimada R; Ozawa T; Toyoda T; Tsuchiya T; Iinuma H; Nozawa K; Matsuda K
Int J Colorectal Dis; 2019 Aug; 34(8):1491-1496. PubMed ID: 31309326
[TBL] [Abstract][Full Text] [Related]
30. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
31. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N
J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638
[TBL] [Abstract][Full Text] [Related]
32. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.
Lavacchi D; Fancelli S; Roviello G; Castiglione F; Caliman E; Rossi G; Venturini J; Pellegrini E; Brugia M; Vannini A; Bartoli C; Cianchi F; Pillozzi S; Antonuzzo L
Front Oncol; 2022; 12():1055019. PubMed ID: 36523988
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and prognostic value of the
Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
[TBL] [Abstract][Full Text] [Related]
35. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations.
Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
Onco Targets Ther; 2016; 9():833-43. PubMed ID: 26955281
[TBL] [Abstract][Full Text] [Related]
36. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
37. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
[TBL] [Abstract][Full Text] [Related]
39. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
[TBL] [Abstract][Full Text] [Related]
40. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
Wang Q; Tang Z; Li C; Li X; Su C
Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
